Full Text Journal Articles by
Author Armando Santoro

Advertisement

Find full text journal articles






Single-cell profiling reveals the dynamics of cytomegalovirusspecific T-cells in haploidentical hematopoietic stem cell transplantation.

Jasper J P Van Beek, Simone Puccio, Alessandra Roberto, Federica De Paoli, Giulia Graziano, Elisa Salviato, Giorgia Alvisi, Veronica Zanon, Alice Scarpa, Elisa Zaghi, Michela Calvi, Clara Di Vito, Rossana Mineri, Barbara Sarina, Chiara De Philippis, Armando Santoro, Jacopo Mariotti, Stefania Bramanti, Francesco Ferrari, Luca Castagna, Domenico Mavilio, Enrico Lugli,

Not available. ... Read more >>

Haematologica (Haematologica)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinical relevance of clonal hematopoiesis in the oldest-old population.

Marianna Rossi, Manja Meggendorfer, Matteo Zampini, Mauro Tettamanti, Emma Riva, Erica Travaglino, Matteo Bersanelli, Sara Mandelli, Alessia Antonella Galbussera, Ettore Mosca, Elena Saba, Chiara Chiereghin, Nicla Manes, Chiara Milanesi, Marta Ubezio, Lucio Morabito, Clelia Peano, Giulia Soldà, Rosanna Asselta, Stefano Duga, Carlo Selmi, Maria De Santis, Karolina Malik, Giulia Maggioni, Maria Elena Bicchieri, Alessia Campagna, Cristina Astrid Tentori, Antonio Russo, Efrem Civilini, Paola Allavena, Rocco Piazza, Giovanni Corrao, Claudia Sala, Alberto Termanini, Laura Giordano, Paolo Detoma, Aurelio Malabaila, Luca Sala, Stefano Rosso, Roberto Zanetti, Claudia Saitta, Elena Riva, Gianluigi Condorelli, Francesco Passamonti, Armando Santoro, Francesc Sole, Uwe Platzbecker, Pierre Fenaux, Niccolo Bolli, Gastone Castellani, Wolfgang Kern, George Vassiliou, Torsten Haferlach, Ugo Lucca, Matteo G Della Porta,

Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased risk of cancers and inflammation-related diseases. This phenomenon becomes very common in oldest-old individuals, in whom the implications of CHIP are not well defined. We performed a mutational screening in 1794 oldest-old individuals enrolled in two population-based studies and investigate ... Read more >>

Blood (Blood)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.

Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T Estrem, Michael Man, Shuaicheng Wang, Michael M Lahn, Eric Raymond, Karim A Benhadji, Sandrine Faivre,

[This corrects the article DOI: 10.1371/journal.pone.0222259.]. ... Read more >>

PLoS One (PloS one)
[2021, 16(6):e0253671]

Cited: 0 times

View full text PDF listing >>



Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical HSCT.

Elisa Zaghi, Michela Calvi, Simone Puccio, Gianmarco Spata, Sara Terzoli, Clelia Peano, Alessandra Roberto, Federica De Paoli, Jasper Jp van Beek, Jacopo Mariotti, Chiara De Philippis, Barbara Sarina, Rossana Mineri, Stefania Bramanti, Armando Santoro, Vu Thuy Khanh Le-Trilling, Mirko Trilling, Emanuela Marcenaro, Luca Castagna, Clara Di Vito, Enrico Lugli, Domenico Mavilio,

Haploidentical hematopoietic stem cell transplantation (h-HSCT) represents an efficient curative approach for patients affected by hematologic malignancies in which the reduced intensity conditioning induces a state of immunologic tolerance between donor and recipient. However, opportunistic viral infections greatly affect h-HSCT clinical outcomes. NK cells are the first lymphocytes that recover ... Read more >>

JCI Insight (JCI insight)
[2021, 6(12):]

Cited: 0 times

View full text PDF listing >>



Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients.

Elisa Lucchini, Chiara Rusconi, Mario Levis, Francesca Ricci, Armando Santoro, Umberto Ricardi, Stefano Volpetti, Fabio Matrone, Anna di Russo, Manuela Caizzi, Anna Schiattarella, Francesco Zaja,

The rate of complete remission (CR) with the anti-PD1 immune checkpoint inhibitors (ICI) nivolumab (N) and pembrolizumab (P) in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) is low (20-30%), and the majority of patients eventually relapse. One strategy to improve their outcome is to combine ICI with radiotherapy (ICI-RT), ... Read more >>

Hematol Rep (Hematology reports)
[2021, 13(2):9080]

Cited: 0 times

View full text PDF listing >>



CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.

Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Mirelis Acosta-Rivera, Su-Pin Choo, Anthony B El-Khoueiry, Ryoko Kuromatsu, Bassel El-Rayes, Kazushi Numata, Yoshito Itoh, Francesco Di Costanzo, Oxana Crysler, Maria Reig, Yun Shen, Jaclyn Neely, Marina Tschaika, Tami Wisniewski, Bruno Sangro,

<h4>Background & aims</h4>Patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B liver function are often excluded from clinical trials. In previous studies, overall survival for these patients treated with sorafenib was ∼3-5 months; thus, new treatments are needed. Nivolumab, alone or in combination with ipilimumab, is conditionally approved in the ... Read more >>

J Hepatol (Journal of hepatology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

Karen A Gelmon, Peter A Fasching, Fergus J Couch, Judith Balmaña, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Graham Walker, Joyce O'Shaughnessy, ,

<h4>Background</h4>In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 152:68-77]

Cited: 0 times

View full text PDF listing >>



Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients: Sympathetic nervous system activity on breast cancer: the story of migraine.

Rita De Sanctis, Alessandro Viganò, Rosalba Torrisi, Armando Santoro,

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 152:250-251]

Cited: 0 times

View full text PDF listing >>



It was hard enough: the spectre of COVID-19 on the management of sarcoma patients.

Andrea Marrari, Nicolò Gennaro, Umberto Cariboni, Vittorio Lorenzo Quagliuolo, Federico D'Orazio, Ferdinando Cananzi, Armando Santoro, Alexia Francesca Bertuzzi,

Eur J Cancer Prev (European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP))
[2021, :]

Cited: 0 times

View full text PDF listing >>



Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy.

Alexia F Bertuzzi, Michele Ciccarelli, Andrea Marrari, Nicolò Gennaro, Andrea Dipasquale, Laura Giordano, Umberto Cariboni, Vittorio Lorenzo Quagliuolo, Marco Alloisio, Armando Santoro,

<h4>Background</h4>The impact of active cancer in COVID-19 patients is poorly defined; however, most studies showed a poorer outcome in cancer patients compared to the general population.<h4>Methods</h4>We analysed clinical data from 557 consecutive COVID-19 patients. Uni-multivariable analysis was performed to identify prognostic factors of COVID-19 survival; propensity score matching was used ... Read more >>

Br J Cancer (British journal of cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.

Angelo Dipasquale, Arianna Marinello, Armando Santoro,

Hepatocellular carcinoma (HCC) is the fifth most common malignancy across the world. Alongside improvement in local approaches for early stages, the prognosis of patients with advanced disease remains poor. The tyrosine kinase inhibitor sorafenib was the first drug approved for advanced HCC. During the past decade, this has been extensively ... Read more >>

J Hepatocell Carcinoma (Journal of hepatocellular carcinoma)
[2021, 8:241-251]

Cited: 0 times

View full text PDF listing >>



Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M Forde, John Sarantopoulos, Philippe L Bedard, Chia-Chi Lin, F Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A Sabatos-Peyton, Tyler A Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing,

<h4>Purpose</h4>Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with advanced solid tumors.<h4>Patients and methods</h4>Primary objectives of the phase I/Ib part were ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(13):3620-3629]

Cited: 0 times

View full text PDF listing >>



Comment on: "Oncologic Safety of Autologous Fat Grafting in Breast Reconstruction".

Andrea Lisa, Agnese Losurdo, Alberto Testori, Corrado Tinterri, Armando Santoro, Marco Klinger,

Clin Breast Cancer (Clinical breast cancer)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study.

David J Pinato, Lorenza Scotti, Alessandra Gennari, Emeline Colomba-Blameble, Saoirse Dolly, Angela Loizidou, John Chester, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Myria Galazi, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-Lumsden, Johann Colomba, Fanny Pommeret, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Gianpiero Rizzo, Michela Libertini, Charlotte Moss, Joanne S Evans, Beth Russell, Rachel Wuerstlein, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Raquel Liñan, Andrea Marrari, M C Carmona-García, Christopher C T Sng, Carlo Tondini, Oriol Mirallas, Valeria Tovazzi, Vittoria Fotia, Claudia A Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Ariadna R Lloveras, Alvin J X Lee, Thomas Newsom-Davis, Rachel Sharkey, Chris Chung, David García-Illescas, Roxana Reyes, Yien N Sophia Wong, Daniela Ferrante, Javier Marco-Hernández, Isabel Ruiz-Camps, Gianluca Gaidano, Andrea Patriarca, Anna Sureda, Clara Martinez-Vila, Ana Sanchez de Torre, Lorenza Rimassa, Lorenzo Chiudinelli, Michela Franchi, Marco Krengli, Armando Santoro, Aleix Prat, Josep Tabernero, Mieke V Hemelrijck, Nikolaos Diamantis, Alessio Cortellini, ,

<h4>Background</h4>Despite high contagiousness and rapid spread, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across affected nations. Within Europe (EU), the United Kingdom (UK) is the most severely affected country, with a death toll in excess of 100,000 as of January 2021. We aimed to compare ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 150:190-202]

Cited: 1 time

View full text PDF listing >>



Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives.

Pasquale Persico, Elena Lorenzi, Angelo Dipasquale, Federico Pessina, Pierina Navarria, Letterio S Politi, Armando Santoro, Matteo Simonelli,

Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. Despite significant efforts, no therapies have demonstrated valuable survival benefit beyond the current standard of care. Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape and improved patient survival in many advanced malignancies. Unfortunately, these clinical successes ... Read more >>

J Clin Med (Journal of clinical medicine)
[2021, 10(7):]

Cited: 1 time

View full text PDF listing >>



Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Elisa Agostinetto, Daniel Eiger, Matteo Lambertini, Marcello Ceppi, Marco Bruzzone, Noam Pondé, Chris Plummer, Ahmad H Awada, Armando Santoro, Martine Piccart-Gebhart, Evandro de Azambuja,

<h4>Background</h4>Immune checkpoint inhibitors (ICIs) may cause potentially life-threatening adverse events (AEs), but the risk of cardiotoxicity has not been fully investigated. It is also unknown whether ICI combinations increase cardiotoxicity compared with single ICI. We aimed to assess the cardiotoxicity of ICI in a range of tumour types.<h4>Methods</h4>This systematic review ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 148:76-91]

Cited: 1 time

View full text PDF listing >>



Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab.

Rita De Sanctis, Laura Giordano, Federica D'Antonio, Elisa Agostinetto, Arianna Marinello, Daniela Guiducci, Giovanna Masci, Agnese Losurdo, Monica Zuradelli, Rosalba Torrisi, Armando Santoro,

<h4>Background</h4>Few data are available about real-life cardiotoxicity associated with s.c. versus i.v. trastuzumab treatment of early-stage, HER2-positive breast cancer, and little is known about its predisposing factors.<h4>Patients and methods</h4>We retrospectively reviewed data of 363 adult patients treated with adjuvant trastuzumab for HER2-positive breast cancer. Univariate statistical analysis was performed, and ... Read more >>

Breast (Breast (Edinburgh, Scotland))
[2021, 57:80-85]

Cited: 1 time

View full text PDF listing >>



Nonmyeloablative Conditioning Regimen Including Low-Dose Total Marrow/Lymphoid Irradiation Before Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Advanced Lymphoproliferative Diseases.

Barbara Sarina, Pietro Mancosu, Pierina Navarria, Stefania Bramanti, Jacopo Mariotti, Chiara De Philippis, Elena Clerici, Ciro Franzese, Daniele Mannina, Viviana Valli, Carmelo Carlo-Stella, Marta Scorsetti, Armando Santoro, Luca Castagna,

Low-dose total body irradiation (TBI) has long been used in nonmyeloablative conditioning (NMAC) regimens before allogeneic stem cell transplantation from haploidentical donors (haplo-SCT). More recently, the use of total marrow lymphoid irradiation (TMLI) instead of TBI in conditioning is increasing. This study aimed to evaluate outcomes in a cohort of ... Read more >>

Transplant Cell Ther (Transplantation and cellular therapy)
[2021, 27(6):492.e1-492.e6]

Cited: 0 times

View full text PDF listing >>



Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Goncalves, Jose S R de Oliveira, Valeria Buccheri, Guilherme F Perini, Neta Goldschmidt, Iryna Kriachok, Michael Dickinson, Mieczyslaw Komarnicki, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Ying Zhu, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, ,

<h4>Background</h4>PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we present interim analyses from the KEYNOTE-204 study evaluating pembrolizumab versus brentuximab vedotin for relapsed or refractory classical Hodgkin lymphoma.<h4>Methods</h4>In this randomised, open-label, phase 3 study, patients aged 18 ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(4):512-524]

Cited: 2 times

View full text PDF listing >>



Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs.

Elena Lorenzi, Matteo Simonelli, Pasquale Persico, Angelo Dipasquale, Armando Santoro,

<h4>Introduction</h4>As the population of young cancer survivors is increasing and a trend toward postponing pregnancy later in life is reported, more efforts are focused toward understanding treatment-induced sequelae, in particular, the effects of cancer and/or treatment on fertility.<h4>Area covered</h4>Whereas the fertility risk of cytotoxic agents for both men and women ... Read more >>

Expert Opin Drug Saf (Expert opinion on drug safety)
[2021, 20(5):503-521]

Cited: 0 times

View full text PDF listing >>



Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score.

Gino M Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C T Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-Lumsden, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Pavetha Seeva, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Charlotte Moss, Beth Russell, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Raquel Liñan, Andrea Marrari, M Carmen Carmona-García, Neha Chopra, Carlo Alberto Tondini, Oriol Mirallas, Valeria Tovazzi, Vittoria Fotia, Claudia Andrea Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Ariadna Roqué, Alvin J X Lee, Tom Newsom-Davis, David García-Illescas, Roxana Reyes, Yien Ning Sophia Wong, Daniela Ferrante, Lorenza Scotti, Javier Marco-Hernández, Isabel Ruiz-Camps, Andrea Patriarca, Lorenza Rimassa, Lorenzo Chiudinelli, Michela Franchi, Armando Santoro, Aleix Prat, Alessandra Gennari, Mieke Van Hemelrijck, Josep Tabernero, Nikolaos Diamantis, David J Pinato, ,

<h4>Background</h4>Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2021, 9(3):]

Cited: 1 time

View full text PDF listing >>



Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.

Rosanna Asselta, Luca Di Tommaso, Matteo Perrino, Annarita Destro, Laura Giordano, Giulia Cardamone, Luca Rubino, Armando Santoro, Stefano Duga, Paolo Andrea Zucali,

<h4>Background</h4>Significant efforts have been made to investigate the molecular pathways involved in thymic carcinogenesis. However, genetic findings have still not impacted clinical practice. The aim of this exploratory trial was to evaluate the immunoscore and molecular profile of a series of thymic carcinomas (TCs), correlating this data with clinical outcome.<h4>Methods</h4>Formalin-fixed, ... Read more >>

Thorac Cancer (Thoracic cancer)
[2021, 12(9):1271-1278]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?

Rosalba Torrisi, Emilia Marrazzo, Elisa Agostinetto, Rita De Sanctis, Agnese Losurdo, Giovanna Masci, Corrado Tinterri, Armando Santoro,

Indication for neoadjuvant chemotherapy (NACT) in HR+/HER2-negative tumors is controversial. Pathological complete response (pCR) rates range from 0 to 18 % while breast-conserving surgery (BCS) is achievable in up to 60 % of tumors. No pathological feature definitely predicts pCR; lobular and molecular luminal A tumors are less likely to ... Read more >>

Crit Rev Oncol Hematol (Critical reviews in oncology/hematology)
[2021, 160:103280]

Cited: 0 times

View full text PDF listing >>



Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Reid W Merryman, Luca Castagna, Laura Giordano, Vincent T Ho, Paolo Corradini, Anna Guidetti, Beatrice Casadei, David A Bond, Samantha Jaglowski, Michael A Spinner, Sally Arai, Robert Lowsky, Gunjan L Shah, Miguel-Angel Perales, Jean Marc Schiano De Colella, Didier Blaise, Alex F Herrera, Geoffrey Shouse, Chloe Spilleboudt, Stephen M Ansell, Yago Nieto, Talha Badar, Mehdi Hamadani, Tatyana A Feldman, Lori Dahncke, Anurag K Singh, Joseph P McGuirk, Taiga Nishihori, Julio Chavez, Anthony V Serritella, Justin Kline, Mohamad Mohty, Remy Dulery, Aspasia Stamatoulas, Roch Houot, Guillaume Manson, Marie-Pierre Moles-Moreau, Corentin Orvain, Kamal Bouabdallah, Dipenkumar Modi, Radhakrishnan Ramchandren, Lazaros Lekakis, Amer Beitinjaneh, Matthew J Frigault, Yi-Bin Chen, Ryan C Lynch, Stephen D Smith, Uttam Rao, Michael Byrne, Jason T Romancik, Jonathon B Cohen, Sunita Nathan, Tycel Phillips, Robin M Joyce, Maryam Rahimian, Asad Bashey, Hatcher J Ballard, Jakub Svoboda, Valter Torri, Martina Sollini, Chiara De Philippis, Massimo Magagnoli, Armando Santoro, Philippe Armand, Pier Luigi Zinzani, Carmelo Carlo-Stella,

Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. ... Read more >>

Leukemia (Leukemia)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Clinical challenges in an unusual setting: ST-elevation in a patient suffering from graft versus host disease, between thrombosis and coronary spasm.

Gaetano Liccardo, Elena Corrada, Letizia Bertoldi, Martina Briani, Jorge Sanz-Sanchez, Mauro Chiarito, Jacopo Mariotti, Chiara de Philippis, Armando Santoro, Bernhard Reimers, Damiano Regazzoli,

Cardiovasc Revasc Med (Cardiovascular revascularization medicine : including molecular interventions)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.175 s